GemVax&KAEL Co.Ltd (082270) Fair Value & Analysis
Technology · KR · Market cap 439B KRW
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Risks
Fair value as of: Aug 21, 2026
From 8 valuation models · updated today
Share price +3.9% over the past month.
Below-average quality, and screening another 91% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,284 KRW). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
60‑month range 9,190 KRW – 69,800 KRW · fair‑value band 852.47 KRW – 1,284 KRW · the 10,120 KRW price screens above the 954.48 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 21, 2026.
Analysis
GemVax&KAEL Co.Ltd (082270) currently trades at 10,120 KRW, while our model-based Fair Value estimate is 954.48 KRW, implying the stock looks roughly 90.6% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, GemVax&KAEL Co.Ltd generated revenue of 78.9B KRW at a net margin of -8.2%. Revenue grew 54.2% year over year. Net debt stands at 40.0B KRW. Fundamentals as of Aug 21, 2026
Our scenario range runs from 852.47 KRW (bear case) to 1,284 KRW (bull case); at 10,120 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Technology peers we cover trades at -56% fair-value upside, at -91%, 082270 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (2,119 KRW) versus Dividend Discount (196.95 KRW). Highest evidence: ROIC Compounder (72).
Notify me when 082270 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 6
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea.
Full company description
GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea. The company offers impregnated active carbon and inorganic adsorbent coating resins; CA filter for removing chemical pollution substances and harmful gases in semiconductor and LCD/PDP manufacturing process; adsorbent towers for air pollution prevention; and pressure facility for preventing equipment erosion within a substation; and 5aver, a fire evacuation mask. It also engages in the research and development of anti-cancer immunotherapeutic and peptide drugs; and provides RIAVAX, an immunotherapeutic peptide for the treatment of locally advanced or metastatic pancreatic cancer. The company was founded in 1998 and is headquartered in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GemVax&KAEL Co.Ltd reported revenue of 81.5B KRW in FY2025 versus 60.4B KRW in FY2021, a compound +7.8%/yr. Reported net income was −11.3B KRW in FY2025.
082270 screens 91% overvalued. Compare with TES Co →
Peer Group
Semiconductors & Semiconductor Equipment · 49 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Semiconductors & Semiconductor Equipment stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| TES Co 095610 | 144,000 KRW | 57,543 KRW | -60% |
| Eugene Technology Co 084370 | 129,200 KRW | 47,495 KRW | -63% |
| TSE Co 131290 | 256,000 KRW | 83,925 KRW | -67% |
| ISC Co 095340 | 159,800 KRW | 61,198 KRW | -62% |
| PSK HOLDINGS Inc 031980 | 112,200 KRW | 74,962 KRW | -33% |
| Jeju Semiconductor Corp 080220 | 87,000 KRW | 23,830 KRW | -73% |
| Tokai Carbon Korea Co 064760 | 229,000 KRW | 154,525 KRW | -33% |
| HANA Micron Inc 067310 | 36,650 KRW | 16,102 KRW | -56% |
| RFHIC Corporation 218410 | 51,000 KRW | 29,096 KRW | -43% |
| S&S Tech Corporation 101490 | 44,850 KRW | 60,781 KRW | +36% |
Compare GemVax&KAEL Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is GemVax&KAEL Co.Ltd (082270) overvalued or undervalued?
What is the fair value of 082270?
What is the quality score of 082270?
What is the revenue of GemVax&KAEL Co.Ltd (082270)?
What is the net profit margin of 082270?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GemVax&KAEL Co.Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.